Vascular brain burden is the greatest determinant of late-life cognition. People with stroke are at increased risk of cognitive decline and dementia, and yet are usually excluded from intervention studies. We need to target high-risk populations to reduce dementia risk and identify genetic and protein markers for post-stroke cognitive decline.
Currently, alteplase is the standard clot-dissolving therapy for ischemic stroke, however this treatment is only effective in 30-45% of patients. Importantly, treatment of ischemic stroke is more effective when given within 90 minutes of stroke onset. Means of treating patients earlier with more effective therapies are needed.